The value of radiotherapy in treating recurrent prostate cancer after radical prostatectomy

Nature Clinical Practice Urology

Volumn 1, Issue 2, 2004, Pages 90-96

  Stephenson, Andrew J ^a   Slawin, Kevin M ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Biochemical recurrence; Prostate cancer; Prostate specific antigen; Radiotherapy; Salvage therapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BIOCHEMISTRY; BONE METASTASIS; CANCER GRADING; CANCER GROWTH; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CLINICAL TRIAL; EARLY DIAGNOSIS; HIGH RISK PATIENT; HUMAN; MALE; NOMOGRAM; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RADIATION BEAM; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME;

HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 20444440680     PISSN: 17434270     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncpuro0056     Document Type: Review

References (45)

1. Brandeis J et al. (2000) A nationwide charge comparison of the principal treatments for early stage prostate carcinoma. Cancer 89: 1792-1799
2. Moul JW (2000) Prostate specific antigen only progression of prostate cancer. J Urol 163: 1632-1642
3. Hull GW et al. (2002) Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 167: 528-534
4. Han M et al. (2001) Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 28: 555-565
5. Roehl KA et al. (2004) Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 172: 910-914
6. Stamey TA et al. (1999) Biological determinants of cancer progression in men with prostate cancer. JAMA 281: 1395-1400
7. Zincke H et al. (1994) Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 152: 1850-1857
8. American Society for Therapeutic Radiology and Oncology Consensus Panel (1997) Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37: 1035-1041
9. Amling CL et al. (2001) Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 165: 1146-1151
10. Patel A et al. (1997) Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 158: 1441-1445
11. Pound CR et al. (1999) Natural history of progression after PSA elevation following radical prostatectomy. Jama 281: 1591-1597
12. Roberts SG et al. (2001) PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 76: 576-581
13. D'Amico AV et al. (2003) Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95: 1376-1383
14. Holzbeierlein JM et al. (2004) Complications of androgen deprivation therapy: prevention and treatment. Oncology (Huntingt) 18: 303-309
15. Krupski TL et al. (2004) Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy. Cancer 101: 541-549
16. Ornstein DK et al. (1998) Evaluation and management of men whose radical prostatectomies failed: results of an international survey. Urology 52: 1047-1054
17. Partin AW et al. (1994) Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 43: 649-659
18. Mehta SS et al. (2004) Patterns of secondary cancer treatment for biochemical failure following radical prostatectomy: data from CaPSURE. J Urol 171: 215-219
19. Holmberg L et al. A (2002) randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 347: 781-789
20. Leventis AK et al. (2001) Local recurrence after radical prostatectomy: correlation of US features with prostatic fossa biopsy findings. Radiology 219: 432-439
21. Raj GV et al. (2002) Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer 94: 987-996
22. Lightner DJ et al. (1990) Prostate specific antigen and local recurrence after radical prostatectomy. J Urol 144: 921-926
23. Leventis AK et al. (2001) Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol 19: 1030-1039
24. Sella T et al. (2004) Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 231: 379-385
25. Stephenson AJ et al. (2004) Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 291, 1325-1332
26. Song DY et al. (2002) Salvage radiotherapy for rising or persistent PSA after radical prostatectomy. Urology 60: 281-287
27. Pisansky TM et al. (2000) Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J Urol 163: 845-850
28. Koppie TM et al. (2001) Is anastomotic biopsy necessary before radiotherapy after radical prostatectomy? J Urol 166: 111-115
29. Thomas CT et al. (2003) Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. J Clin Oncol 21: 1715-1721
30. Cher ML et al. (1998) Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol 160: 1387-1391
31. Katz MS et al. (2003) Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol 21: 483-489
32. Cadeddu JA et al. (1998) Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol 159: 173-177
33. Vicini FA et al. (1999) Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer. Urology 54: 111-117
34. Valicenti RK et al. (1998) Durable efficacy of early postoperative radiation therapy for high-risk pT3N0 prostate cancer: the importance of radiation dose. Urology 52: 1034-1040
35. Maier J et al. (2004) Salvage radiation for a rising PSA following radical prostatectomy. Urol Oncol 22: 50-56
36. Cox JD et al. (1999) Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J Clin Oncol 17: 1155
37. Anscher MS et al. (2000) Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: the first 10 years. Int J Radiat Oncol Biol Phys 48: 369-375
38. Wu JJ et al. (1995) The efficacy of postprostatectomy radiotherapy in patients with an isolated elevation of serum prostate-specific antigen. Int J Radiat Oncol Biol Phys 32: 317-323
39. Zelefsky MJ et al. (2002) High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53: 1111-1116
40. Zelefsky MJ et al. (1998) Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 41: 491-500
41. Stephenson AJ et al. (2003) Predicting the outcome of salvage radiotherapy for suspected local recurrence of prostate cancer after radical prostatectomy [abstract 1577]. In: Proceedings of the American Society of Clinical Oncology 39th Annual Meeting: May 30-June 3 2003; Chicago, IL, 392 (Ed. Marshall JL) Alexandria, VA: American Society of Clinical Oncology
42. Bolla M et al. (2004) Does postoperative radiotherapy after radical prostatectomy improve progression-free survival in pT3N0 prostate cancer? [abstract 4540]. In: Proceedings of the American Society of Clinical Oncology 40th Annual Meeting: June 5-8 2004; New Orleans LA, 382 (Ed. Grunberg SM) Alexandria, VA: American Society of Clinical Oncology
43. Chawla AK et al. (2002) Salvage radiotherapy after radical prostatectomy for prostate adenocarcinoma: analysis of efficacy and prognostic factors. Urology 59: 726-731
44. Liauw SL et al. (2003) Salvage radiotherapy for biochemical failure of radical prostatectomy: a single-institution experience. Urology 61: 1204-1210
45. Van Cangh PJ et al. (1998) Adjuvant radiation therapy does not cause urinary incontinence after radical prostatectomy: results of a prospective randomized sudy. J Urol 159: 164-166